Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO(BMY) · Entity 1662 | VP, Tax and Treasury | March 02, 2004 | March 04, 2004 |
| Tvardi Therapeutics, Inc.CARA · Entity 7579 | Director | June 01, 2023 | June 05, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BRISTOL MYERS SQUIBB CO
Report date March 02, 2004 · Filed March 04, 2004
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.10 par valueSEC Table I · non-derivative | Direct | 70,652 |
Reported balance
After 2004-03-02 transaction · row 1
1 source rowRow 1 · 2004-03-02 · Grant · Acquired 4,167 · Balance 70,652 F1: Shares consist of restricted stock with one-third vesting on each of the third, fourth and fifth anniversaries of the grant date. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.11 · Expires 2014-03-01 | Direct | 25,000 |
Reported balance
After 2004-03-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2004-03-02 · Grant · Acquired 25,000 · Balance 25,000 F2: Exercisable as to 25% of the shares annually, on a cumulative basis, commencing one year after the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares consist of restricted stock with one-third vesting on each of the third, fourth and fifth anniversaries of the grant date.
F2: Exercisable as to 25% of the shares annually, on a cumulative basis, commencing one year after the date of grant.
Tvardi Therapeutics, Inc.
Report date June 01, 2023 · Filed June 05, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 57,438 |
Reported balance
After 2023-06-01 transaction · row 1
1 source rowRow 1 · 2023-06-01 · Grant · Acquired 32,362 · Balance 57,438 F1: Represents the number of shares underlying restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of (i) June 1, 2024 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.09 · Expires 2033-06-01 | Direct | 44,961 |
Reported balance
After 2023-06-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-06-01 · Grant · Acquired 44,961 · Balance 44,961 F2: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 1, 2024 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares underlying restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of (i) June 1, 2024 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date.
F2: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 1, 2024 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 01, 2023 Filed Jun 5, 2023 16:31 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantStock Option (Right to Buy) · Derivative | 44,961 | $0.00 Strike: $3.09 | $0.00 |
DisclosureSEC source: 0001209191-23-034322 · doc4.xml · derivative · entry 2 BAINS HARRISON M JR · CIK 0001202282 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,961 Underlying: Common Stock · 44,961 shares Expires 2033-06-01 F2 · derivative.exercise_date: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 1, 2024 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 16:31 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 32,362 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-034322 · doc4.xml · nonDerivative · entry 1 BAINS HARRISON M JR · CIK 0001202282 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,438 F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of (i) June 1, 2024 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. Read SEC document |
| July 15, 2022 Filed Jul 19, 2022 17:13 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 7,200 | $9.05 | $65,160.00 |
DisclosureSEC source: 0001209191-22-042604 · doc4.xml · nonDerivative · entry 1 BAINS HARRISON M JR · CIK 0001202282 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,076 F1 · kind: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on June 15, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.97 to $9.37, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| June 02, 2022 Filed Jun 6, 2022 17:50 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantStock Option (Right to Buy) · Derivative | 16,996 | $0.00 Strike: $8.42 | $0.00 |
DisclosureSEC source: 0001209191-22-034625 · doc4.xml · derivative · entry 2 BAINS HARRISON M JR · CIK 0001202282 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,996 Underlying: Common Stock · 16,996 shares Expires 2032-06-02 F2 · derivative.exercise_date: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 2, 2023 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. Read SEC document |
| June 02, 2022 Filed Jun 6, 2022 17:50 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 11,876 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-034625 · doc4.xml · nonDerivative · entry 1 BAINS HARRISON M JR · CIK 0001202282 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,276 F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of (i) June 2, 2023 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 19:24 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantStock Option (Right to Buy) · Derivative | 10,800 | $0.00 Strike: $13.06 | $0.00 |
DisclosureSEC source: 0001209191-21-038759 · doc4.xml · derivative · entry 2 BAINS HARRISON M JR · CIK 0001202282 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,800 Underlying: Common Stock · 10,800 shares Expires 2031-06-03 F2 · derivative.exercise_date: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 3, 2022 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 19:24 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 7,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-038759 · doc4.xml · nonDerivative · entry 1 BAINS HARRISON M JR · CIK 0001202282 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,400 F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of (i) June 3, 2022 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 17:48 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantStock Option (Right to Buy) · Derivative | 10,800 | $0.00 Strike: $15.62 | $0.00 |
DisclosureSEC source: 0001209191-20-035067 · doc4.xml · derivative · entry 2 BAINS HARRISON M JR · CIK 0001202282 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,800 Underlying: Common Stock · 10,800 shares Expires 2030-06-04 F2 · derivative.exercise_date: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 4, 2021 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 17:48 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 7,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-035067 · doc4.xml · nonDerivative · entry 1 BAINS HARRISON M JR · CIK 0001202282 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,200 F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of (i) June 4, 2021 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. Read SEC document |
| June 04, 2019 Filed Jun 6, 2019 18:00 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantStock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $20.44 | $0.00 |
DisclosureSEC source: 0001209191-19-035218 · doc4.xml · derivative · entry 2 BAINS HARRISON M JR · CIK 0001202282 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2029-06-04 F2 · derivative.exercise_date: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 4, 2020 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. Read SEC document |
| June 04, 2019 Filed Jun 6, 2019 18:00 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-035218 · doc4.xml · nonDerivative · entry 1 BAINS HARRISON M JR · CIK 0001202282 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of (i) June 4, 2020 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 16:30 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $16.07 | $0.00 |
DisclosureSEC source: 0001209191-18-036694 · doc4.xml · derivative · entry 1 BAINS HARRISON M JR · CIK 0001202282 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2028-06-06 F1 · derivative.exercise_date: This option was granted to the reporting person pursuant to the issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on June 6, 2019, subject to the reporting person's continued service as a director through such date. Read SEC document |
| June 21, 2017 Filed Jun 23, 2017 18:34 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $19.50 | $0.00 |
DisclosureSEC source: 0001209191-17-041747 · doc4.xml · derivative · entry 1 BAINS HARRISON M JR · CIK 0001202282 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-21 F1 · derivative.exercise_date: This option was granted to the reporting person pursuant to the issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on June 21, 2018, subject to the reporting person's continued service as a director through such date. Read SEC document |
| March 02, 2004 Filed Mar 4, 2004 22:24 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | GrantOption (right to buy) · Derivative | 25,000 | $0.00 Strike: $28.11 | $0.00 |
DisclosureSEC source: 0000014272-04-000065 · bai217.xml · derivative · entry 2 BAINS HARRISON M JR · CIK 0001202282 · VP, Tax and Treasury 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock, $0.10 par value · 25,000 shares Expires 2014-03-01 F2 · derivative.exercise_date: Exercisable as to 25% of the shares annually, on a cumulative basis, commencing one year after the date of grant. Read SEC document |
| March 02, 2004 Filed Mar 4, 2004 22:24 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | GrantCommon Stock, $0.10 par value | 4,167 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-04-000065 · bai217.xml · nonDerivative · entry 1 BAINS HARRISON M JR · CIK 0001202282 · VP, Tax and Treasury 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,652 F1 · shares: Shares consist of restricted stock with one-third vesting on each of the third, fourth and fifth anniversaries of the grant date. Read SEC document |
| March 01, 2004 Filed Mar 2, 2004 19:43 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 1,790 | $28.04 | $50,191.60 |
DisclosureSEC source: 0000014272-04-000047 · bai215.xml · nonDerivative · entry 1 BAINS HARRISON M JR · CIK 0001202282 · VP, Tax and Treasury 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,485 F1 · kind: Shares withheld for payment of taxes upon vesting of restricted stock. Read SEC document |
| July 09, 2003 Filed Jul 10, 2003 20:08 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | Exercise / conversionOption (right to buy) · Derivative | 50,479 | $0.00 Strike: $14.74 | $0.00 |
DisclosureSEC source: 0000014272-03-000016 · bai147.xml · derivative · entry 4 BAINS HARRISON M JR · CIK 0001202282 · VP, Tax and Treasury 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 50,479 shares Expires 2005-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 09, 2003 Filed Jul 10, 2003 20:08 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 10,139 | $27.49 | $278,721.11 |
DisclosureSEC source: 0000014272-03-000016 · bai147.xml · nonDerivative · entry 3 BAINS HARRISON M JR · CIK 0001202282 · VP, Tax and Treasury 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,275 F2 · shares: Shares withheld for payment of taxes upon exercise of stock option. Read SEC document |
| July 09, 2003 Filed Jul 10, 2003 20:08 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 27,065 | $27.49 | $744,016.85 |
DisclosureSEC source: 0000014272-03-000016 · bai147.xml · nonDerivative · entry 2 BAINS HARRISON M JR · CIK 0001202282 · VP, Tax and Treasury 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Shares withheld for payment of exercise price. Read SEC document |
| July 09, 2003 Filed Jul 10, 2003 20:08 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 50,479 | $14.74 | $744,060.46 |
DisclosureSEC source: 0000014272-03-000016 · bai147.xml · nonDerivative · entry 1 BAINS HARRISON M JR · CIK 0001202282 · VP, Tax and Treasury 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.